Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04855760 · ClinicalTrials.gov registry record · Phase 3
Safety of REL-1017 for Major Depressive Disorder
A Phase 3 study, sponsored by Relmada Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 627
- Enrollment target
NCT04855760 is a Phase 3 study that has completed, run by Relmada Therapeutics. The registered enrollment target is 627 participants.
The verdict
NCT04855760, a Phase 3 study, has completed, sponsored by Relmada Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 627 participants
- Enrollment target
Study Summary
This was a 1-year, multicenter, open-label, long-term study to assess the safety of REL-1017 once daily (QD) as monotherapy or as adjunctive treatment of Major Depressive Disorder. Adjunctive study participants continued to take their current antidepressant therapy in addition to the study drug for the duration of the treatment period.
Interventions
- DRUG REL-1017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04855760
The ClinicalTrials.gov registry entry for NCT04855760 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 627 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Relmada Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REL-1017 is the first listed.
NCT04855760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04855760 about?
NCT04855760 is a clinical study titled "Safety of REL-1017 for Major Depressive Disorder". This was a 1-year, multicenter, open-label, long-term study to assess the safety of REL-1017 once daily (QD) as monotherapy or as adjunctive treatment of Major Depressive Disorder. Adjunctive study participants continued to take their current antidepressant therapy in addition to the study drug for ...
What is the current status of trial NCT04855760?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 627 participants. The study started on 2021-04-01. Estimated completion is 2023-07-27.
What interventions are being tested in trial NCT04855760?
The interventions under investigation include: REL-1017 (DRUG).
Who is sponsoring clinical trial NCT04855760?
This trial is sponsored by Relmada Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.